Annexon, Inc. will present at the J.P. Morgan Healthcare Conference on January 14, 2026, discussing targeted immunotherapies.
Quiver AI Summary
Annexon, Inc., a biopharmaceutical company focused on creating targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million people globally, has announced that its CEO, Douglas Love, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m. PST. Interested parties can access a live webcast of the presentation on Annexon's website, which will also host an archived replay for 30 days afterward. The company emphasizes its innovative approach targeting C1q to address harmful neuroinflammation while aiming to develop transformative therapies for patients.
Potential Positives
- Douglas Love, the CEO, will present at a prestigious industry event, the 44th Annual J.P. Morgan Healthcare Conference, highlighting the company's visibility and credibility in the biopharmaceutical sector.
- The presentation at a major conference provides an opportunity to attract investor interest and support for Annexon's innovative therapies aimed at neuroinflammatory diseases affecting nearly 10 million people globally.
- The focus on targeted immunotherapies for serious conditions positions Annexon as a leader in addressing significant unmet medical needs, enhancing its appeal to stakeholders in the healthcare community.
- The live and archived webcast of the presentation allows for broader outreach and engagement with potential investors and industry partners, increasing transparency and interest in the company's developments.
Potential Negatives
- None
FAQ
What is the focus of Annexon, Inc.?
Annexon, Inc. focuses on developing targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million people worldwide.
When will Annexon's CEO present at the J.P. Morgan Healthcare Conference?
Douglas Love, CEO of Annexon, will present at the conference on January 14, 2026, at 11:15 a.m. PST.
How can I access the webcast of Annexon's presentation?
The live webcast can be accessed on Annexon’s Investors page under the ‘Events & Presentations’ section at www.annexonbio.com.
Will there be a replay of the presentation available?
Yes, a replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
What is Annexon's mission?
Annexon's mission is to deliver innovative therapies that help patients with neuroinflammatory diseases live their best lives.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANNX Insider Trading Activity
$ANNX insiders have traded $ANNX stock on the open market 14 times in the past 6 months. Of those trades, 11 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ANNX stock by insiders over the last 6 months:
- MUNEER A SATTER has made 5 purchases buying 2,322,613 shares for an estimated $8,655,783 and 0 sales.
- JUNG CHOI purchased 33,000 shares for an estimated $138,270
- WILLIAM H. CARSON has made 5 purchases buying 20,575 shares for an estimated $70,695 and 0 sales.
- JENNIFER LEW (EVP & CHIEF FINANCIAL OFFICER) sold 1,117 shares for an estimated $2,881
- TED YEDNOCK (EVP & CHIEF INNOVATION OFFICER) sold 1,116 shares for an estimated $2,879
- MICHAEL OVERDORF (EVP & CHIEF BUSINESS OFFICER) sold 853 shares for an estimated $2,226
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANNX Hedge Fund Activity
We have seen 85 institutional investors add shares of $ANNX stock to their portfolio, and 54 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 4,614,063 shares (-29.4%) from their portfolio in Q3 2025, for an estimated $14,072,892
- SIO CAPITAL MANAGEMENT, LLC removed 4,095,764 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $12,492,080
- OPALEYE MANAGEMENT INC. added 2,600,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $7,930,000
- LOGOS GLOBAL MANAGEMENT LP removed 2,410,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,350,500
- MORGAN STANLEY added 2,197,308 shares (+263.9%) to their portfolio in Q3 2025, for an estimated $6,701,789
- WOODLINE PARTNERS LP added 1,584,566 shares (+150.4%) to their portfolio in Q3 2025, for an estimated $4,832,926
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,500,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,575,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANNX Analyst Ratings
Wall Street analysts have issued reports on $ANNX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 11/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/15/2025
To track analyst ratings and price targets for $ANNX, check out Quiver Quantitative's $ANNX forecast page.
$ANNX Price Targets
Multiple analysts have issued price targets for $ANNX recently. We have seen 4 analysts offer price targets for $ANNX in the last 6 months, with a median target of $16.5.
Here are some recent targets:
- Daniil Gataulin from Chardan Capital set a target price of $16.0 on 12/23/2025
- Bill Maughan from Clear Street set a target price of $17.0 on 12/02/2025
- Derek Archila from Wells Fargo set a target price of $27.0 on 11/19/2025
- Ananda Ghosh from HC Wainwright & Co. set a target price of $14.0 on 08/15/2025
Full Release
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com . A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
[email protected]
Media Contact:
Beth Keshishian
917-912-7195
[email protected]
